Plasma cell myeloma refractory
RecruitingStudy of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma
Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma
- Disease:Plasma cell myeloma refractory
- Substances:Belantamab MafodotinBortezomib+3
France- Participants:18–64 years · 65+ years
- Substances:Belantamab Mafodotin
- Sponsor:Glaxosmithkline Research & Development Limited









